Literature DB >> 26699910

CDK6 mediates the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy.

Weiwei Yuan1, Chunmei Tang2, Wensi Zhu2, Jiening Zhu1, Qiuxiong Lin1, Yongheng Fu1, Chunyu Deng1, Yumei Xue1, Min Yang1, Shulin Wu1, Zhixin Shan3.   

Abstract

MicroRNA-1 (miR-1) is approved involved in cardiac hypertrophy, but the underlying molecular mechanisms of miR-1 in cardiac hypertrophy are not well elucidated. The present study aimed to investigate the potential role of miR-1 in modulating CDKs-Rb pathway during cardiomyocyte hypertrophy. A rat model of hypertrophy was established with abdominal aortic constriction, and a cell model of hypertrophy was also achieved based on PE-promoted neonatal rat ventricular cardiomyocytes (NRVCs). We demonstrated that miR-1 expression was markedly decreased in hypertrophic myocardium and hypertrophic cardiomyocytes. Dual luciferase reporter assays revealed that miR-1 interacted with the 3'UTR of CDK6, and miR-1 was verified to inhibit CDK6 expression at the posttranscriptional level. CDK6 protein expression was observed increased in hypertrophic myocardium and hypertrophic cardiomyocytes. Morover, miR-1 mimic, in parallel to CDK6 siRNA, could inhibit PE-induced hypertrophy of NRVCs, with decreases in cell size, newly transcribed RNA, expressions of ANF and β-MHC, and the phosphorylated pRb. Taken together, our results reveal that derepression of CDK6 and activation of Rb pathway contributes to the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy.

Entities:  

Keywords:  CDK6; Cardiac hypertrophy; Cardiomyocyte; MicroRNA-1

Mesh:

Substances:

Year:  2015        PMID: 26699910     DOI: 10.1007/s11010-015-2635-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  25 in total

Review 1.  Role of D-type cyclins in heart development and disease.

Authors:  Adam Hotchkiss; Jessica Robinson; Jessica MacLean; Tiam Feridooni; Karim Wafa; Kishore B S Pasumarthi
Journal:  Can J Physiol Pharmacol       Date:  2012-08-17       Impact factor: 2.273

2.  Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy.

Authors:  Dharmesh Vara; Katrina A Bicknell; Carmen H Coxon; Gavin Brooks
Journal:  J Biol Chem       Date:  2003-04-06       Impact factor: 5.157

3.  Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy.

Authors:  Qing Li; Xiao-Wei Song; Jun Zou; Guo-Kun Wang; Elena Kremneva; Xiang-Qi Li; Ni Zhu; Tao Sun; Pekka Lappalainen; Wen-Jun Yuan; Yong-Wen Qin; Qing Jing
Journal:  J Cell Sci       Date:  2010-06-22       Impact factor: 5.285

4.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure.

Authors:  Eva van Rooij; Lillian B Sutherland; Ning Liu; Andrew H Williams; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-15       Impact factor: 11.205

5.  Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro.

Authors:  Peter K Busk; Jirina Bartkova; Claes C Strøm; Linda Wulf-Andersen; Rebecca Hinrichsen; Tue E H Christoffersen; Lucia Latella; Jiri Bartek; Stig Haunsø; Søren P Sheikh
Journal:  Cardiovasc Res       Date:  2002-10       Impact factor: 10.787

6.  Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy.

Authors:  Mariko Tatsuguchi; Hee Young Seok; Thomas E Callis; J Michael Thomson; Jian-Fu Chen; Martin Newman; Mauricio Rojas; Scott M Hammond; Da-Zhi Wang
Journal:  J Mol Cell Cardiol       Date:  2007-04-14       Impact factor: 5.000

7.  MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.

Authors:  Thomas E Callis; Kumar Pandya; Hee Young Seok; Ru-Hang Tang; Mariko Tatsuguchi; Zhan-Peng Huang; Jian-Fu Chen; Zhongliang Deng; Bronwyn Gunn; Janelle Shumate; Monte S Willis; Craig H Selzman; Da-Zhi Wang
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

8.  MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.

Authors:  Haibing Xiao; Jin Zeng; Heng Li; Ke Chen; Gan Yu; Junhui Hu; Kun Tang; Hui Zhou; Qihong Huang; Anping Li; Yi Li; Zhangqun Ye; Ji Wang; Hua Xu
Journal:  Oncotarget       Date:  2015-05-30

9.  Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.

Authors:  Shuai Huang; Xiao Zou; Jie-Ning Zhu; Yong-Heng Fu; Qiu-Xiong Lin; Ye-You Liang; Chun-Yu Deng; Su-Juan Kuang; Meng-Zhen Zhang; Yu-Lin Liao; Xi-Long Zheng; Xi-Yong Yu; Zhi-Xin Shan
Journal:  J Cell Mol Med       Date:  2015-01-13       Impact factor: 5.310

10.  Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy.

Authors:  R Hinrichsen; A H Hansen; S Haunsø; P K Busk
Journal:  Cell Prolif       Date:  2008-10       Impact factor: 6.831

View more
  16 in total

1.  [CircRNA_005647 inhibits expressions of fibrosis-related genes in mouse cardiac fibroblasts via sponging miR-27b-3p].

Authors:  Shujing Yuan; Jingnan Liang; Ming Zhang; Jiening Zhu; Rong Pan; Hui Li; Ni Zeng; Yihong Wen; Zhiyao Yi; Zhixin Shan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-11-30

2.  Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.

Authors:  Huan Wang; Robert P Sheehan; Adam C Palmer; Robert A Everley; Sarah A Boswell; Noga Ron-Harel; Alison E Ringel; Kristina M Holton; Connor A Jacobson; Alison R Erickson; Laura Maliszewski; Marcia C Haigis; Peter K Sorger
Journal:  Cell Syst       Date:  2019-05-08       Impact factor: 10.304

Review 3.  Noncoding RNAs in Cardiac Hypertrophy.

Authors:  Yongqin Li; Yajun Liang; Yujiao Zhu; Yuhui Zhang; Yihua Bei
Journal:  J Cardiovasc Transl Res       Date:  2018-08-31       Impact factor: 4.132

4.  Suppression of the Inhibitory Effect of circ_0036176-Translated Myo9a-208 on Cardiac Fibroblast Proliferation by miR-218-5p.

Authors:  Jing Guo; Li-Wen Chen; Zhi-Qi Huang; Ji-Shen Guo; Hui Li; Yue Shan; Ze-Run Chen; Yu-Min Yan; Jie-Ning Zhu; Hui-Ming Guo; Xian-Hong Fang; Zhi-Xin Shan
Journal:  J Cardiovasc Transl Res       Date:  2022-03-14       Impact factor: 3.216

Review 5.  The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling.

Authors:  Michaela Adamcova; Ippei Kawano; Fedor Simko
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

6.  CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts.

Authors:  Chun-Mei Tang; Ming Zhang; Lei Huang; Zhi-Qin Hu; Jie-Ning Zhu; Zhen Xiao; Zhuo Zhang; Qiu-Xiong Lin; Xi-Long Zheng; Min -Yang; Shu-Lin Wu; Jian-Ding Cheng; Zhi-Xin Shan
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

7.  Renal denervation attenuates cardiac hypertrophy in spontaneously hypertensive rats via regulation of autophagy.

Authors:  Jionghua Huang; He Huang; Wei Pan; Dejin Ou; Wenjun Dai; Yuhui Lin; Jinlei Wu; Wenjie Xie; Ximing Chen
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

8.  Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity.

Authors:  Jie-Ning Zhu; Yong-Heng Fu; Zhi-Qin Hu; Wen-Yu Li; Chun-Mei Tang; Hong-Wen Fei; Hui Yang; Qiu-Xiong Lin; De-Ming Gou; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

9.  Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice.

Authors:  Zhi-Qin Hu; Jian-Fang Luo; Xue-Ju Yu; Jie-Ning Zhu; Lei Huang; Jing Yang; Yong-Heng Fu; Tao Li; Yu-Mei Xue; Ying-Qing Feng; Zhi-Xin Shan
Journal:  Oncotarget       Date:  2017-09-08

10.  Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts.

Authors:  Wen-Si Zhu; Chun-Mei Tang; Zhen Xiao; Jie-Ning Zhu; Qiu-Xiong Lin; Yong-Heng Fu; Zhi-Qin Hu; Zhuo Zhang; Min Yang; Xi-Long Zheng; Shu-Lin Wu; Zhi-Xin Shan
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.